Gilead Sciences(CH:GILD)
CHFÂ 141.18+0.80 (+0.57%)
CH:GILD
Gilead Sciences stock forecast
CHFÂ 141.18
At close:+0.80 (+0.57%)
Gilead Sciences (GILD) Stock Forecast & Price Target
4 Followers
GILD Analyst Ratings
Strong Buy
18Buy5Hold0Sell
Based on 23 analysts giving stock ratings to Gilead Sciences in the past 3 months
GILD Stock 12 Month Forecast
Average Price Target
CHF144.61â–²(2.43% Upside)Based on 23 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is CHF 144.61 with a high forecast of CHF 166.45 and a low forecast of CHF 109.02. The average price target represents a 2.43% change from the last price of CHF 141.18.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF166.45
AverageCHF144.61
LowCHF109.02
Highest Price TargetHighestCHF166.45Average Price TargetCHF144.61Lowest Price TargetLowestCHF109.02
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Jasper Hellweg | Argus Research | CHF70.74→CHF158.13 | buy | 12.00%Upside | Reiterated | 11/11/26 | ||
| Louise Chen | Scotiabank | CHF166.45 | buy | 17.90%Upside | Reiterated | 11/10/26 | ||
| Michael Okunewitch | Maxim Group | ― | buy | ― | Reiterated | 11/05/26 | ||
| Brian Abrahams | RBC Capital | CHF109.02 | hold | -22.78%Downside | Reiterated | 11/05/26 | ||
| Geoff Meacham | Citi | CHF149.81→CHF156.46 | buy | 10.83%Upside | Reiterated | 11/04/26 | ||
| Evan Seigerman | BMO Capital | CHF153.13 | buy | 8.47%Upside | Reiterated | 11/02/26 | ||
| Daina Graybosch | Leerink Partners | CHF107.36→CHF120.68 | hold | -14.52%Downside | Reiterated | 11/02/26 | ||
| Mohit Bansal | Wells Fargo | CHF137.32→CHF158.13 | buy | 12.00%Upside | Assigned | 10/30/26 | ||
| Joseph Stringer | Needham | CHF141.48→CHF166.45 | buy | 17.90%Upside | Reiterated | 10/30/26 | ||
| Michael Yee | UBS | CHF145.64→CHF162.29 | buy | 14.95%Upside | Assigned | 10/30/26 | ||
| Terence Flynn | Morgan Stanley | CHF135.66→CHF152.30 | buy | 7.88%Upside | Assigned | 10/30/26 | ||
| Tyler Van Buren | TD Cowen | CHF133.16→CHF145.64 | buy | 3.16%Upside | Reiterated | 10/30/26 | ||
| Chris Schott | J.P. Morgan | CHF141.48→CHF158.13 | buy | 12.00%Upside | Assigned | 10/30/26 | ||
| Gregory Renza | Truist Financial | CHF131.50→CHF150.64 | buy | 6.70%Upside | Reiterated | 10/30/26 | ||
| Umer Raffat | Evercore ISI | ― | buy | ― | Reiterated | 10/30/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Jasper HellwegArgus Research | BuyReiteratedCHF70.74→CHF158.13 | 11/11/26 | 12.00%Upside | ||
| Louise ChenScotiabank | BuyReiteratedCHF166.45 | 11/10/26 | 17.90%Upside | ||
| Michael OkunewitchMaxim Group | BuyReiterated | 11/05/26 | ― | ||
| Brian AbrahamsRBC Capital | HoldReiteratedCHF109.02 | 11/05/26 | -22.78%Downside | ||
| Geoff MeachamCiti | BuyReiteratedCHF149.81→CHF156.46 | 11/04/26 | 10.83%Upside | ||
| Evan SeigermanBMO Capital | BuyReiteratedCHF153.13 | 11/02/26 | 8.47%Upside | ||
| Daina GrayboschLeerink Partners | HoldReiteratedCHF107.36→CHF120.68 | 11/02/26 | -14.52%Downside | ||
| Mohit BansalWells Fargo | BuyAssignedCHF137.32→CHF158.13 | 10/30/26 | 12.00%Upside | ||
| Joseph StringerNeedham | BuyReiteratedCHF141.48→CHF166.45 | 10/30/26 | 17.90%Upside | ||
| Michael YeeUBS | BuyAssignedCHF145.64→CHF162.29 | 10/30/26 | 14.95%Upside | ||
| Terence FlynnMorgan Stanley | BuyAssignedCHF135.66→CHF152.30 | 10/30/26 | 7.88%Upside | ||
| Tyler Van BurenTD Cowen | BuyReiteratedCHF133.16→CHF145.64 | 10/30/26 | 3.16%Upside | ||
| Chris SchottJ.P. Morgan | BuyAssignedCHF141.48→CHF158.13 | 10/30/26 | 12.00%Upside | ||
| Gregory RenzaTruist Financial | BuyReiteratedCHF131.50→CHF150.64 | 10/30/26 | 6.70%Upside | ||
| Umer RaffatEvercore ISI | BuyReiterated | 10/30/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Gilead Sciences
3 Months
Success Rate17/21 ratings generated profit
81%
Average Return
+8.33%
Copying Courtney Breen's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +8.33% per trade.
1 Year
Success Rate21/21 ratings generated profit
100%
Average Return
+30.68%
Copying Courtney Breen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +30.68% per trade.
2 Years
Success Rate30/30 ratings generated profit
100%
Average Return
+62.01%
Copying Tyler Van Buren's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +62.01% per trade.
GILD Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 53 | 56 | 35 | 51 | 38 |
| Hold | 13 | 11 | 9 | 12 | 11 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 66 | 67 | 44 | 63 | 49 |
In the current month, GILD has received 38 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. GILD average Analyst price target in the past 3 months is 144.61.
GILD Financial Forecast
HighCHF1.75
ConsensusCHF1.06
LowCHF0.76
GILD Earnings Forecast
Next quarter’s earnings estimate for GILD is CHF 1.06 with a range of CHF 0.76 to CHF 1.75. The previous quarter’s EPS was CHF 2.10. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF7.04B
ConsensusCHF6.85B
LowCHF6.67B
GILD Sales Forecast
Next quarter’s sales forecast for GILD is CHF 6.85B with a range of CHF 6.67B to CHF 7.04B. The previous quarter’s sales results were CHF 6.85B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
GILD Stock Forecast FAQ
What is CH:GILD’s average 12-month price target, according to analysts?
Based on analyst ratings, Gilead Sciences’s 12-month average price target is CHF144.61.
What is CH:GILD’s upside potential, based on the analysts’ average price target?
Gilead Sciences has 2.43% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Gilead Sciences a Buy, Sell or Hold?
Gilead Sciences has a consensus rating of Strong Buy, which is based on 18 buy ratings, 5 hold ratings and 0 sell ratings.
What is Gilead Sciences’s share price target?
The average share price target for Gilead Sciences is CHF144.61. This is based on 23 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF166.45, and the lowest forecast is CHF109.02. The average share price target represents a 2.43% increase from the current price of CHF141.18.
What do analysts say about Gilead Sciences?
Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Street analysts.
How can I buy shares of Gilead Sciences?
To buy shares of CH:GILD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
